Fig. 8: Early treatment with PMX205 suppresses neurofilament light levels in plasma of Arc mice. | Nature Communications

Fig. 8: Early treatment with PMX205 suppresses neurofilament light levels in plasma of Arc mice.

From: C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer’s disease mouse model

Fig. 8

a Plasma NfL levels of WT and Arctic mice before (pre) and after (post) PMX205 or water treatment from 7.5 to 10 months. b Plasma NfL levels in WT and Arc pretreatment and at 7 mo after (post) PMX205 treatment for 2, 6, or 12 weeks. Data shown as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001, Repeated measures Two-way ANOVA with Tukey’s post hoc, WT-H2O (post tx) vs Arc- H2O (post tx) p = 0.002; WT-PMX (post tx) vs Arc-PMX (post tx) p = 0.0316. N = 16 (WT- H2O), 16 (WT-PMX), 14 (Arc- H2O) and 10 (Arc-PMX) (a) and Sidak’s post hoc, Arc vs WT, p = 0.0004; Arc vs Arc-PMX 12 wk p = 0.13; Arc vs Arc-PMX 6 wk p = 0.0018; Arc vs Arc-PMX 2 wk p = 0.0486. N = 6 (WT- H2O), 3 (Arc- H2O), 4 (Arc-PMX 12 wk), 6 (Arc-PMX 6 wk), and 6 (Arc-PMX 2 wk) (b). Males and females were included in both studies with no apparent sex differences evident in any genotype/treatment group.

Back to article page